Business Review for the year ended December 31, 2013

• 2013: solid 4.6% organic growth in sales
  
  • At the top end of the target range announced early in the year
  • Faster organic growth in North America and firmer business in Western Europe
  • Sustained fast growth in industrial applications, up 6.8%
• 2013 objective for operating income before non-recurring items confirmed
• Marcy l'Etoile, France - January 22, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2013.
• Sales for the year ended December 31, 2013 amounted to €1,588 million, representing a 4.6% year-on-year increase at constant exchange rates and scope of consolidation. Excluding the €7 million from R&D-related revenue, organic growth would have come to 4.1% for the year.
• Fourth-quarter sales amounted to €444 million, representing a very robust 6.5% organic gain, over the 2012 fourth-quarter which already reported strong growth.
• “2013 was an important, constructive year in bioMérieux’s 2012 - 2015 roadmap,” said Jean-Luc Belingard, Chairman and Chief Executive Officer. “Sales rose by an organic 4.6%, led by the robust expansion in North America (up 4.8%) and emerging markets and lifted by the firmer conditions in Western Europe. VIDAS® 3 was successfully introduced in Europe and VITEK® MS is the only mass spectrometry system cleared by the FDA for use by microbiology laboratories in the routine detection of a comprehensive menu of disease-causing microorganisms. Lastly, we acquired U.S.-based BioFire Diagnostics, whose revolutionary FilmArray® molecular biology system will be one of our leading growth drivers. Our sales performance was in line with the objective set at the beginning of the year, enabling us to confirm our EBIT* target for 2013. In addition, 2014, which will be a year of investment and consolidation, will also see further robust organic growth in sales, which we are targeting at 3% to 5% before taking into account adverse currency effects and the consolidation of an estimated €60 million in additional sales from BioFire.”

Contacts

Investor Relations
bioMérieux
Isabelle Tongio
Tél. : + 33 4 78 87 22 37
investor.relations@biomerieux.com

Media Relations
bioMérieux                                    Image Sept
Aurore Sergeant                           Laurence Heilbronn                           Claire Doligez

Tél. : + 33 4 78 87 51 97             Tél. : + 33 1 53 70 74 64                    Tél. : + 33 1 53 70 74 48
media@biomerieux.com            lheilbronn@image7.fr                        cdoligez@image7.fr